Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination

Oncology

Volumn 69, Issue 2, 2005, Pages 135-144

  Piga, Andrea ^a,h   Gesuita, Rosaria ^b   Catalano, Vincenzo ^c   Nortilli, Rolando ^d   Cetto, Gianluigi ^d   Cardillo, Francesca ^e   Giorgi, Francesca ^f   Riva, Nada ^g   Porfiri, Emilio ^c   Montironi, Rodolfo ^b   Carle, Flavia ^b   Cellerino, Riccardo ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Medical Oncology   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e City Hospital   (Italy)

^f Universit degli Studi di Padova   (Italy)

^g City Hospital   (Italy)

^h UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Multivariate analysis; Primary tumors; Prognostic factors; Survival; Treatment outcome; Unknown

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; PLATINUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, UNKNOWN PRIMARY; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 25444484957     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087837     Document Type: Article

References (55)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-2103.
2. Greco FA, Hainsworth JD: Cancer of unknown primary site; in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott-Raven, 2001, pp 2537-2560.
3. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Unknown primary tumors metastatic to liver. J Clin Oncol 1998;16:2105-2112.
4. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL: Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 1997;15:2056-2066.
5. Muggia FM, Baranda J: Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol 1993;20:268-272.
6. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
7. Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, Bafaloukos D, Maraveyas A, Fountzilas G: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol 1992;3:631-634.
8. Saghatchian M, Fizazi K, Borel C, Ducreux M, Ruffie P, Le Chevalier T, Theodore C: Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study. Ann Oncol 2001;12:535-540.
9. van der Gaast A, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G: Carcinoma of unknown primary: Identification of a treatable subset? Ann Oncol 1990;1:119-122.
10. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P: Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-1280.
11. Alberts AS, Falkson G, Falkson HC, van der Merwe MP: Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients. Med Pediatr Oncol 1989;17:188-192.
12. Altman C, Cadman E: An analysis of 1539 patients with unknown primary site. Cancer 1986;57:120-124.
13. Culine S, Gazagne L, Ychou M, Romieu G, Fabbro M, Cupissol D, Dubois JB: Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevention. Rev Med Interne 1998;19:713-719.
14. Kambhu SA, Kelsen DP, Fiore J: Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results. Am J Clin Oncol 1980;25:1053-1055.
15. Lortholary A, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E: Cancers of unknown origin: 311 cases. Bull Cancer 2001;88:619-627.
16. Pasterz R, Savaray N, Burgess M: Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986;4:1652-1657.
17. Piga A, Nortilli R, Cetto GL, Cardarelli N, Fedeli SL, Fiorentini G, D'Aprile M, Giorgi F, Parziale AP, Contu A, Montironi R, Gesuita R, Carle F, Cellerino R: Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer 2004;90:1898-1904.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Mantel N, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1958;22:718-748.
21. Cox DR: Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
22. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-3107.
23. Briasoulis E, Tsavaris N, Fountzilas G, Athanasiadis A, Kosmidis P, Bafaloukos D, Skarlos D, Samantas E, Pavlidis N: Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology 1998;55:426-430.
24. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F: Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002;94:840-846.
25. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pujol H: Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy. Ann Oncol 1999;10:569-575.
26. Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; The Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI01): Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-3482.
27. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR: A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001;91:592-597.
28. Falkson CI, Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998;55:116-121.
29. Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD: Carcinoma of unknown primary site. Cancer 2000;89:2655-2660.
30. Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network Study. J Clin Oncol 2002;20:1651-1656.
31. Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD: Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
32. Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, Schneider M: Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: A phase II trial. Am J Clin Oncol 2001;24:372-375.
33. Lofts FJ, Gogas H, Mansi JL: Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam). Ann Oncol 1999;10:1389-1392.
34. Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY: A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 2002;86:1238-1242.
35. Parnis FX, Olver IN, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T: Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 2000;11:883-884.
36. Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, Cupissol D, Pinguet F: Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-1261.
37. Rigg A, Cunningham D, Gore M, Hill M, O'Brien M, Nicolson M, Chang J, Watson M, Norman A, Hill A, Oates J, Moore H, Ross P: A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 1997;75:101-105.
38. Voog E, Merrouche Y, Trillet-Lenoir V, Lasset C, Peaud PY, Rebattu P, Negrier S: Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000;23:614-616.
39. Warner E, Goel R, Chang J, Chow W, Verma S, Dancey J, Franssen E, Dulude H, Girouard M, Correia J, Gallant G: A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer 1998;77:2376-2380.
40. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K; French Study Group on Carcinomas of Unknown Primary: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-4683.
41. van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995;13:1720-1725.
42. Farrugia DC, Norman AR, Nicolson MC, Gore M, Bolodeoku EO, Webb A, Cunningham D: Unknown primary carcinoma: Randomised studies are needed to identify optimal treatments and their benefits. Eur J Cancer 1996;32A:2256-2261.
43. Hansen HH, Daugaard G: Management of carcinoma of unknown primary site (CUP), any changes? Ann Oncol 2001;12:431-432.
44. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999;5:3403-3410.
45. Califano J, Westra WH, Koch W, Meininger G, Reed A, Yip L, Boyle JO, Lonardo F, Sidransky D: Unknown primary head and neck squamous cell carcinoma: Molecular identification of the site of origin. J Natl Cancer Inst 1999;91:599-604.
46. Simon R, Mirlacher M, Sauter G: Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn 2003;3:421-430.
47. Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-662.
48. Alizadeh AA, Ross DT, Perou CM, van de Rijn M: Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52.
49. Guo QM: DNA microarray and cancer. Curr Opin Oncol 2003;15:36-43.
50. Hampton GM, Frierson HF: Classifying human cancer by analysis of gene expression. Trends Mol Med 2003;9:5-10.
51. Macgregor PF, Squire JA: Application of microarrays to the analysis of gene expression in cancer. Clin Chem 2002;48:1170-1177.
52. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA: Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683-695.
53. Pusztai L, Ayers M, Stec J, Hortobagyi GN: Clinical application of cDNA microarrays in oncology. Oncologist 2003;8:252-258.
54. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF 3rd, Liotta LA: Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004;55:97-112.
55. Varadhachary GR, Abbruzzese JL, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-1785.